What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...
UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.
As men age, their bodies go through many natural changes. One such change, often less spoken about, is the enlargement of the ...
A prescription medication that has been available in the U.S. since 1992 might have another significant benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results